Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Scotland

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links